---
schema_version: "secwatch.filing_event.v1"
accession: "0001048477-24-000013"
form_type: "8-K"
ticker: "BMRN"
cik: "0001048477"
company_name: "BIOMARIN PHARMACEUTICAL INC"
filed_at: "2024-02-22T23:59:59+00:00"
generated_at: "2026-06-05T18:10:39.951560+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BioMarin reports record FY2023 revenue $2.42B (+15% YoY); non-GAAP EPS $2.08 (+36% YoY)

## Summary
- FY2023 total revenues $2.42B (+15% YoY); GAAP diluted EPS $0.87 (+16% YoY); non-GAAP diluted EPS $2.08 (+36% YoY).
- VOXZOGO net revenues $146M in Q4'23 (+118% Q/Q) and $470M for FY'23 (+178% YoY); 2,613 children treated at year-end.
- Q4'23 total revenues $646.2M (+20% YoY); GAAP net income $20.4M vs $0.2M loss in Q4'22.
- 2024 guidance: double-digit total revenue growth, non-GAAP operating margin expansion, EPS growing faster than revenue.
- FDA approved VOXZOGO for children under 5; ~70% of new US starts from that age group in Q4'23.

## SEC filing metadata
- accession: 0001048477-24-000013
- form_type: 8-K
- ticker: BMRN
- cik: 0001048477
- company_name: BIOMARIN PHARMACEUTICAL INC
- filed_at: 2024-02-22T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1048477/000104847724000013/0001048477-24-000013-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1048477/000104847724000013/bmrn-20240222.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001048477-24-000013
- JSON: https://secwatch.observer/filing/0001048477-24-000013.json
- Plain text: https://secwatch.observer/filing/0001048477-24-000013.txt

## Key facts
- Earnings Releases
  BIOMARIN PHARMACEUTICAL INC reported fourth quarter and full year ended December 31, 2023 results: revenue $646.2 million, net income $20.4 million, EPS $0.11. Guidance reaffirmed.
  - Period: fourth quarter and full year ended December 31, 2023
  - Revenue: $646.2 million
  - Net income: $20.4 million
  - EPS: $0.11
  - Guidance: reaffirmed
  - Result: reported results
  source text: plans and convertible debt in periods when they are dilutive under Non-GAAP. nm Not meaningful Financial Highlights: • Total Revenues for the fourth quarter of 2023 were $646.2 million, an increase of 20% compared to the same period in 2022. The increase in Total Revenues was primarily attributed to higher VOXZOGO sales volume driven by new patients initiating
  evidence_url: https://www.sec.gov/Archives/edgar/data/1048477/000104847724000013/0001048477-24-000013-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.